Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

Published:2018-02-01 Issue:2 Volume:4 Page:230
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Jabbour Elias¹,Ravandi Farhad¹,Kebriaei Partow²,Huang Xuelin³,Short Nicholas J.¹,Thomas Deborah¹,Sasaki Koji¹,Rytting Michael¹,Jain Nitin¹,Konopleva Marina¹,Garcia-Manero Guillermo¹,Champlin Richard²,Marin David²,Kadia Tapan¹,Cortes Jorge¹,Estrov Zeev¹,Takahashi Koichi¹,Patel Yogin¹,Khouri Maria R.¹,Jacob Jovitta¹,Garris Rebecca¹,O’Brien Susan⁴,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

2. Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston

3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

4. Chao Family Comprehensive Cancer Center, University of California–Irvine, Orange

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin;Blood Cancer Journal;2024-08-07

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: a systematic review;Heliyon;2024-08

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL;JAMA Oncology;2024-07-01